Luminex (NASDAQ: LMNX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Luminex and Pacific Biosciences of California, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Luminex 0 1 1 0 2.50
Pacific Biosciences of California 0 2 1 0 2.33

Luminex presently has a consensus target price of $22.50, suggesting a potential upside of 18.05%. Pacific Biosciences of California has a consensus target price of $6.27, suggesting a potential upside of 157.89%. Given Pacific Biosciences of California’s higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Luminex.

Institutional & Insider Ownership

76.3% of Luminex shares are owned by institutional investors. Comparatively, 70.5% of Pacific Biosciences of California shares are owned by institutional investors. 6.9% of Luminex shares are owned by insiders. Comparatively, 17.8% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Luminex has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Valuation & Earnings

This table compares Luminex and Pacific Biosciences of California’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Luminex $270.64 million 3.10 $13.81 million $0.66 28.88
Pacific Biosciences of California $93.47 million 3.02 -$92.19 million ($0.89) -2.73

Luminex has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Luminex, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Luminex and Pacific Biosciences of California’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Luminex 9.52% 6.01% 5.47%
Pacific Biosciences of California -98.63% -96.55% -58.68%

Dividends

Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.3%. Pacific Biosciences of California does not pay a dividend. Luminex pays out 36.4% of its earnings in the form of a dividend.

Summary

Luminex beats Pacific Biosciences of California on 11 of the 15 factors compared between the two stocks.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.